drugset / Trial / NCT00493766
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a parallel, two-arm, open-label, multicenter phase IA/IB study of LBH589 (oral formulation) alone and in combination with docetaxel in patients with progressing hormone refractory prostate cancer. This study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg two times a day , and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile
Timeline
- Start
- 2006-05
- Primary completion
- 2008-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | — | Oral |